Company receives ANDA approval to market generic Brivaract 10 mg/mL antiepileptic solution worldwide, produced by Indoco.

• Brivaracetam oral solution matches UCB’s RLD in bioequivalence and therapeutic equivalence, ensuring safety for patients.
• Manufactured at Indoco Remedies’ Goa facility, L‑14 Verna Industrial Area, meeting international quality standards consistently.
• Aditi Panandikar highlights a milestone, reinforcing the company’s commitment to affordable, innovative healthcare across regulated markets globally.